← Eichor
Study identifier: NCT05964712 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study

Condition: Acromegaly  ·  Sponsor: Istituto Auxologico Italiano

PhaseN/A
Planned participants30
Who can joinAll sexes, 18 Years to 90 Years
Healthy volunteersNo

About this study

Acromegaly is a rare chronic disease due to excessive secretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), caused in over 98% of cases by GH-secreting pituitary adenoma. Prolonged exposure to GH/IGF-I excess is the cause of increased mortality and morbidity in these patients. Arthropathy occurs in about 75% of acromegalic patients. Any joint may be affected, with the development of osteoarthritis, arthralgia, and an increase in fracture risk. The aims of the present project are to evaluate the dimensions of hands and feet with the 3D scanner method and to perform a quantitative analysis of movement through Gait Analysis technique in de novo patients with acromegaly (group # 1) and in patients with different disease status (group #2).

This description comes directly from the study's public registry record.

Talk to the study team

Sara Farina, Doctor  ·  +393386822298  ·  sara.farina@unimi.it

Always discuss trial participation with your own doctor first.

Locations (1)

Istituto Auxologico Italiano IRCCS San LucaMilan, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05964712